These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 2347037)

  • 1. The effect of route of administration and fractionation of dose on the metabolism of ifosfamide.
    Lind MJ; Roberts HL; Thatcher N; Idle JR
    Cancer Chemother Pharmacol; 1990; 26(2):105-11. PubMed ID: 2347037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The glycine deportation system and its pharmacological consequences.
    Beyoğlu D; Idle JR
    Pharmacol Ther; 2012 Aug; 135(2):151-67. PubMed ID: 22584143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enantioselective liquid chromatography-mass spectrometry assay for the determination of ifosfamide and identification of the N-dechloroethylated metabolites of ifosfamide in human plasma.
    Oliveira RV; Onorato JM; Siluk D; Walko CM; Lindley C; Wainer IW
    J Pharm Biomed Anal; 2007 Oct; 45(2):295-303. PubMed ID: 17855037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of docetaxel plus ifosfamide in patients with advanced cancer.
    Marx G; Lewis C; Hall K; Levi J; Ackland S
    Br J Cancer; 2002 Oct; 87(8):846-9. PubMed ID: 12373597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
    Kerbusch T; de Kraker J; Keizer HJ; van Putten JW; Groen HJ; Jansen RL; Schellens JH; Beijnen JH
    Clin Pharmacokinet; 2001 Jan; 40(1):41-62. PubMed ID: 11236809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism and pharmacokinetics of oxazaphosphorines.
    Boddy AV; Yule SM
    Clin Pharmacokinet; 2000 Apr; 38(4):291-304. PubMed ID: 10803453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study.
    Singer JM; Hartley JM; Brennan C; Nicholson PW; Souhami RL
    Br J Cancer; 1998 Mar; 77(6):978-84. PubMed ID: 9528844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients.
    Granvil CP; Ducharme J; Leyland-Jones B; Trudeau M; Wainer IW
    Cancer Chemother Pharmacol; 1996; 37(5):451-6. PubMed ID: 8599868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy.
    Gilard V; Malet-Martino MC; de Forni M; Niemeyer U; Ader JC; Martino R
    Cancer Chemother Pharmacol; 1993; 31(5):387-94. PubMed ID: 8431973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy.
    Kurowski V; Wagner T
    Cancer Chemother Pharmacol; 1993; 33(1):36-42. PubMed ID: 8269587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of ifosfamide during a 3 day infusion.
    Hartley JM; Hansen L; Harland SJ; Nicholson PW; Pasini F; Souhami RL
    Br J Cancer; 1994 May; 69(5):931-6. PubMed ID: 8180026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ifosfamide clinical pharmacokinetics.
    Wagner T
    Clin Pharmacokinet; 1994 Jun; 26(6):439-56. PubMed ID: 8070218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion.
    Boddy AV; Cole M; Pearson AD; Idle JR
    Cancer Chemother Pharmacol; 1995; 36(1):53-60. PubMed ID: 7720176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of cyclophosphamide.
    Moore MJ
    Clin Pharmacokinet; 1991 Mar; 20(3):194-208. PubMed ID: 2025981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.
    Boos J; Welslau U; Ritter J; Blaschke G; Schellong G
    Cancer Chemother Pharmacol; 1991; 28(6):455-60. PubMed ID: 1934249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ifosfamide pharmacokinetics.
    Lewis LD
    Invest New Drugs; 1991 Nov; 9(4):305-11. PubMed ID: 1804803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosing and side-effects of ifosfamide plus mesna.
    Brade WP; Herdrich K; Kachel-Fischer U; Araujo CE
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S164-86. PubMed ID: 1795007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study.
    Cerny T; Martinelli G; Goldhirsch A; Terrier F; Joss R; Fey MF; Brunner KW; Küpfer A
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S135-8. PubMed ID: 1795002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous continuous infusion of ifosfamide and cyclophosphamide in ambulatory cancer patients: bioavailability and feasibility.
    Cerny T; Graf A; Rohner P; Zeugin T; Brunner KW; Küpfer A
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S129-34. PubMed ID: 1795001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.
    Dechant KL; Brogden RN; Pilkington T; Faulds D
    Drugs; 1991 Sep; 42(3):428-67. PubMed ID: 1720382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.